GE Healthcare of Piscataway, NJ, has received US Patent No. 8,507,197, "Quality control methods for arrayed oligonucleotides." The provided method involves synthesizing a complement probe oligonucleotide for each oligonucleotide being tested. Probe oligonucleotides are optionally grouped. They are then hybridized to test oligonucleotides, and the hybridized pair is subject to single base extension and detection.
Ohio State University of Columbus, Ohio, has received US Patent No. 8,507,202, "Methods for diagnosing pancreatic cancer using MicroRNAs." The method includes reverse transcribing an miR gene product of miR-221 from a test sample from the subject to provide corresponding miR gene product target oligonucleotides; hybridizing the miR target oligodeoxynucleotides to a microarray; comparing the test sample hybridization profile to a control hybridization profile; and diagnosing the subject as having, or at risk for developing, pancreatic cancer if the level of the miR gene product of miR-221 in the test sample is greater than the control.
The University of Wyoming of Laramie, WY, has received US Patent No. 8,507,208, "Methods and compositions for detection of biological materials using microfluidic devices." Microfluidic devices are provided for the sensitive detection of analytes. There are also methods for detecting direct or indirect binding of enzymes or catalysts to a surface.
Massachusetts Institute of Technology of Cambridge, Mass., has received US Patent No. 8,507,226, "Methods for high fidelity production of long nucleic acid molecules." The patent provides methods for the production of long nucleic acid molecules with user control over sequence content. In a preferred embodiment, long error-free nucleic acid molecules can be generated in parallel from oligonucleotides immobilized on a surface, such as an oligonucleotide microarray. The movement of the growing nucleic acid molecule can be controlled through the stepwise repositioning of the growing molecule.
Academia Sinica of Taipei, Taiwan, has received US Patent No. 8,507,660, "Alpha-selective sialyl phosphate donors for preparation of sialosides and sialoside arrays for influenza virus detection." Libraries of sialosides and methods for using the libraries for detection and receptor binding analysis of surface glycoproteins or pathogens and cancer cells are claimed in this patent. According to the inventors, the synthesized sialosides are spotted onto a substrate to generate a sialoside array for influenza hemagluttin and real virus binding profiling.